Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project
Novo Nordisk appoints new CEO, and more people moves for you to know about
The company acquired Everyday Health in December.
Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer
Novo Nordisk CEO describes 'volatile' pricing environment; Lilly to cut 200 research and development jobs; pharma opts out of Super Bowl this year
Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims
Pharma among top sponsors of Trump inauguration parties; AstraZeneca exec to replace GSK president of global pharmaceuticals; EpiPen rival to relaunch
Biogen to pay $1.25 billion for patents to MS drugs; Supreme Court to hear Novartis case over Zarxio delay; Merck KGaA inks big-data deal
The questions being asked about how drugs are priced are weighing heavily on pharma leaders, and they know the issue is not going away.
The first step is to seek leadership support, she says.
Allergan's board endorses its social contract with patients; drugmakers that market painkillers are hiring DEA officials; the FDA approves new Biogen drug
Biogen names new CEO; the FDA issues two warning letters; Allergan to acquire aesthetics firm
For years pharma has said it needs to be more focused on patients, has it delivered?
Heather Bresch's appearance at industry summit came after she declined to attend a congressional hearing scheduled for the same day.
Valeant doesn't plan to offload Salix; heart docs back Califf as commish; Saunders says pricing issues aren't affected by election
Lilly's experimental Alzheimer's drug fails in another trial; two more patients die during trial for Juno's CAR-T therapy; NEJM launches platform in China
The drugstore chain added drug effectiveness reviews and other information from PatientsLikeMe to its website.
Mylan reports third-quarter loss; analysts say drug-pricing restrictions less likely under Trump; the FDA limits citizen petitions
The new TV spot was developed with CNN and Edelman.
Listen Up was the internal communications element Level Brand created to help employees learn how to improve member experience.
Klick Ideas Exchange united leading CEOs and high-level executives of biotech and pharmaceutical companies, thought leaders, and other industry influencers to explore issues that are shaping the future of healthcare.
Pfizer drops plans to split into two companies; Merck's Keytruda gains competitive edge in China; Apple may be developing health software
The consultancy includes Double Helix, which was acquired by McCann in 2012.
Drugmakers to remove incentives for sales reps marketing antibiotics; Mylan CEO defends EpiPen pricing; fitness trackers don't help people lose weight
GSK names new CEO; the FDA approves first Duchenne muscular dystrophy drug; Sanofi files Lantus patent lawsuit against Merck
Retzlaff files a complaint against Turing; Pfizer to buy antibiotics from AstraZeneca; Mylan's marketing for EpiPen faces criticism
Pfizer's commercial expertise in urology and oncology could help propel Medivation's Xtandi to new heights.
Pfizer to acquire cancer drugmaker Medivation; Valeant names new CFO; Apple acquires health data startup
The current reimbursement climate is more likely to impact how drugmakers order their global product launches than the U.K.'s vote to exit the E.U.
Only one new osteoporosis drug has been approved over the last six years.
- Five things for pharma marketers to know: Wednesday, March 22, 2017
- Five things for pharma marketers to know: Monday, March 20, 2017
- Novartis aims to bring first oral asthma drug to market in two decades
- Drugmakers target severe asthma patients with biologics, but payers raise pricing issue
- Five things for pharma marketers to know: Tuesday, March 21, 2017
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Digital IDs become focus as drugmakers seek to track doctors' behavior online
- Some CME experts remain skeptical when it comes to social media